Caribou Biosciences to shut down after failing to raise CAR-T funding

· Health · United States

Caribou Biosciences, the biotech co-founded by Nobel laureate Jennifer Doudna, is shutting down after failing to raise the money needed to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma. The California company said it is shelving two allogeneic CAR-T cell therapy programs and will pursue strategic alternatives. Despite having a prospect ready for late-stage testing, Caribou could not secure funding amid what it called a challenging financing climate for cell therapy. The closure underscores the difficulty smaller biotechs face in advancing expensive late-stage trials without a partner or a large capital base, even in one of biotech's most closely watched fields.

Why it matters：The shutdown of a Doudna-founded company shows how funding constraints are thinning the field of allogeneic cell therapy developers, potentially slowing a major frontier of cancer treatment.

Key points

  • Caribou will shelve two allogeneic CAR-T cell therapy programs, including one for lymphoma ready for late-stage testing.
  • The company failed to secure funding and will pursue strategic alternatives.
  • Caribou was co-founded by Jennifer Doudna, a Nobel laureate in chemistry.

Sources (original reporting)

More stories from this day